Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04113018 · OUTCOME

Number of Participants Who Discontinued Study Treatment Due to Adverse Events

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma · Source last updated 2026-08-13

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From enrollment to 30 days following cessation of study treatment. Reasons for study treatment discontinuation include progression, toxicity, consent withdrawal, or investigator decision; assessed for approximately 5 years.

What was measured

A binary variable will be determined for each participant indicating whether or not the subject discontinued study treatment due to adverse events.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
A binary variable will be determined for each participant indicating whether or not the subject discontinued study treatment due to adverse events.
reporting Status
NOT_POSTED
time Frame
From enrollment to 30 days following cessation of study treatment. Reasons for study treatment discontinuation include progression, toxicity, consent withdrawal, or investigator decision; assessed for approximately 5 years.
title
Number of Participants Who Discontinued Study Treatment Due to Adverse Events
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice